Pfizer launched activity-tracking and education technologies targeted toward patients with hemophilia, a rare bleeding disorder, Aug. 24.
HemMobile Striiv, a wearable wristband, enables hemophilia patients to track their daily activity and heart rates. It also integrates with HemMobile, a hemophilia app Pfizer launched in 2012 that allows patients to log bleeding and infusions and monitor their factor supply. With the wearable, the app can compile additional personalized reports on a patient's health.
Pfizer also launched Hemocraft, a video game inspired by Minecraft, which aims to educate younger hemophilia patients, aged 8 to 16, about the importance of sticking to one's treatment plan. In the game, players go on a "quest" and interact with a fictional village physician to learn how their treatments work.
"These new digital innovations can be integrated into everyday routines to help empower people with hemophilia to learn about and track different aspects relevant to their disease so that they can have informed conversations with their healthcare providers," said Kevin W. Williams, MD, CMO of Pfizer Rare Disease.